Side-by-side · Research reference

ThymalinvsVesugen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticAUTO-DRAFTED12/40 cited

BAnimal-MechanisticHUMAN-REVIEWED5/43 cited

Thymalin

Immune restorer · Russian peptide bioregulator

5–10 mgPer cycle doseKhavinson 2002

HumanMechanisticKhavinson 2002

HoursHalf-life (est)

IM · Daily for 5–10 days · 1-2×/year

Vesugen

Bioregulatory Tripeptide · Vascular Endothelium

3 AATripeptide

Endothelin-1 ↓Atherosclerotic tissue

Ki-67 ↑Aged endothelium

SQ / IM · Protocol varies

01Mechanism of Action

Parameter

Thymalin

Vesugen

Primary target

T-cell precursors + thymus-axis maturation pathwayKhavinson 2002

Vascular endothelial cell nucleus — MKI67 gene promoter

Pathway

Modulation of T-cell differentiation + thymic hormone restoration in age-involuted thymusKhavinson 2002

KED → MKI67 promoter interaction (CATC binding motif -14 to +12 bp) → Ki-67 proliferation protein ↑

Downstream effect

Restored T-cell populations, improved immune surveillance, reduced infection rates in elderlyKhavinson 2002

Normalised endothelin-1 expression in atherosclerotic/restenotic endothelium, restored connexin expression for cell-cell communication, enhanced proliferative capacity in senescent endothelial culturesKozlov 2016 Khavinson 2014

Feedback intact?

—

Not applicable — does not operate via hormone axis

Origin

Polypeptide fraction isolated from calf thymus extractKhavinson 2002

Khavinson bioregulatory peptide school — designed as tissue-specific (vascular) cytomodulator

Antibody development

—

02Dosage Protocols

Parameter

Thymalin

Vesugen

Standard dose

5–10 mg / day IM × 5–10 daysKhavinson 2002

—

Frequency

Once daily during cycle

Not specified in available literature

Lower / starter dose

2.5 mg / day

—

Evidence basis

Russian clinical + in vitroKhavinson 2002

Animal models (atherosclerosis, restenosis, aging) · Russian case series

Duration

5–10 day cycles, 1–2× per year

Case series report treatment courses in elderly arterial insufficiency

Reconstitution

Saline or bacteriostatic water

—

Timing

Morning preferred

—

Half-life

Hours (estimated)

Not reported

Tripeptides typically cleared rapidly.

Standard dose (reported)

—

Not standardised — Russian clinical case series

Protocols vary; no FDA-approved regimen.

Route

—

Subcutaneous or intramuscular

04Side Effects & Safety

Parameter

Thymalin

Vesugen

Injection site reaction

Mild erythema at IM site

—

Allergic reaction

Rare hypersensitivity to bovine-derived polypeptide

—

Autoimmune flare

Theoretical risk in active autoimmune disease

—

Long-term safety

Limited Western data

Unknown — no long-term RCT data

Pregnancy / OB

Avoid

—

Reported adverse events

—

None documented in available abstracts

Injection site

—

Assumed minimal — typical for small peptides

Epigenetic mechanism risk

—

Theoretical concern: direct gene promoter interaction — proliferative effects in non-target tissues not characterised

Absolute Contraindications

Thymalin

·Pregnancy / breastfeeding
·Bovine protein hypersensitivity

Vesugen

—

Relative Contraindications

Thymalin

·Active autoimmune disease
·Concurrent immunosuppressant therapy

Vesugen

·Active malignancy — proliferative mechanism (Ki-67 upregulation) untested in oncologic context

05Administration Protocol

Parameter

Thymalin

Vesugen

1. Reconstitution

Add 1–2 mL saline or bacteriostatic water per 10 mg vial.

Lyophilised powder reconstituted with sterile water or bacteriostatic water per supplier protocol. No standardised formulation.

2. Injection site

Intramuscular — deltoid or gluteal. Rotate sites.

Subcutaneous (abdomen, thigh) or intramuscular. Rotate sites if multi-dose protocol.

3. Timing

Morning preferred during cycle.

No reported circadian or fasting requirement. Russian protocols typically integrated into geroprotective regimens.

4. Storage

Lyophilised: refrigerate, light-protected. Reconstituted: use immediately.

Lyophilised: refrigerate 2–8 °C, light-protected. Reconstituted: use immediately or refrigerate per supplier guidance (typically <7 days).

5. Needle

23–25G, 25–38 mm IM needle.

—

06Stack Synergy

Thymalin

+ Thymosin α-1

Moderate

View Thymosin α-1 →

Thymalin is a polypeptide complex; Thymosin α-1 is a single purified peptide. Both target the thymus-axis but at different levels — Thymalin restores broad thymic signaling; Tα-1 provides a specific molecular activator. Anecdotally combined for elderly immune support.

Thymalin: 5–10 mg IM · daily × 7 days
Thymosin α-1: 1.6 mg SQ · 2× weekly during the cycle
Primary benefit: Broad thymic restoration + targeted immune activation

Khavinson 2002 Camerini 2001

Vesugen

+ Thymalin

Multi-pathway

View Thymalin →

Both from Khavinson bioregulatory school. Thymalin targets thymic/immune axis, Vesugen targets vascular endothelium. Rationale: multi-system geroprotection in elderly — immune senescence + vascular aging. Documented in Khavinson-tradition protocols combining tissue-specific peptides for poly-organ rejuvenation. No direct synergy study; combinatorial logic based on distinct target tissues.

Vesugen: Per protocol (SQ/IM)
Thymalin: Per protocol (SQ/IM)
Frequency: Sequential or concurrent per geroprotective protocol
Primary benefit: Multi-system age-related decline mitigation (vascular + immune)